Can Early Treatment With Azilect Slow Parkinson's?
Study Is Fuzzy, but Suggests a Benefit From Azilect in Early Parkinson's Disease
WebMD News Archive
Sept. 23, 2009 -- A study suggests that the drug Azilect may slow
Parkinson's if started early in the disease, but contradictory data fog the
The brains of patients with Parkinson's disease are starved for dopamine.
Azilect, a drug approved for Parkinson's treatment, slows the breakdown of
dopamine and other brain chemicals.
There's reason to think that Azilect may do more than treat Parkinson's
symptoms. It may actually slow the relentless progression of Parkinson's
How can that be proved? C. Warren Olanow, MD, of Mount Sinai School of
Medicine, New York, and colleagues tried a daring study. They enrolled 1,176
patients with early, untreated Parkinson's disease in a two-phase study.
In the first phase, half the patients got Azilect at doses of either 1
milligram or 2 milligrams a day. The other half got a placebo. But it would be
unethical to withhold an effective treatment for long, so after 36 weeks, the
placebo patients started getting Azilect, too.
If all the patients were doing equally well after 72 weeks, one could
conclude that Azilect simply treats the symptoms of Parkinson's disease. But if
those who started treatment earlier were still doing better at that time, then
any difference should be because of the slowing of Parkinson's disease
It's a daring study because so much can go wrong with a study design like
this. The study went as planned, but the results were unexpected.
Early treatment at the 1 milligram dose of Azilect did seem to slow
Parkinson's disease. But early treatment at the 2 milligram dose did not.
"It is difficult to explain why the two doses did not provide similar
results," Olanow and colleagues note.
Although they conclude that the 1 milligram dose of Azilect may very well
slow Parkinson's disease, "the study results must be interpreted with
The study findings appear in the Sept. 24 issue of The New England
Journal of Medicine. The study was funded by Teva Pharmaceuticals, which
makes Azilect. Olanow and some of his colleagues report receiving consulting
and/or lecture fees from Teva and other pharmaceutical companies.